[1]
“ЭFFICACY AND TOLERABILITY OF LENVATINIB IN RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER”, WEJMMS, vol. 2, no. 6, pp. 11–20, Jun. 2024, Accessed: Jan. 31, 2026. [Online]. Available: https://westerneuropeanstudies.com/index.php/3/article/view/1131